Preclinical Oncology & Immuno-Oncology Studies
Accelerating oncology & immuno-oncology drug development through the most cutting-edge animal models of cancer.
- Indications
- Services
- About Us
- News
- Blog
- Contact
Timeliness. Experience. Responsiveness. State of the art instruments and animal models. These are the foundations upon which PharmaLegacy was built. It is why we’ve been trusted by 12 of the top 20 pharmaceutical companies, and how we’ve supported over 400 INDs.
When it comes to the models, they need to be as diverse and complex as cancer itself. PharmaLegacy has hundreds of in-vivo tumor models, including xenograft, syngeneic and humanized models, which we supplement with in-vitro and ex-vivo panels and analyses, so you come as close as possible to predicting clinical performance.
With our scientific staff averaging over 15 years of experience, there is no cutting corners. You can simply expect more when you choose PharmaLegacy as your preclinical oncology CRO.
PharmaLegacy’s human cancer cell panel serves as an important tool for anti-cancer drug discovery, enabling rapid and efficient evaluation of potential cytotoxicity and growth-inhibition effects of test compounds against multi-type tumors. More than 200 human cancer cells can be screened by our cell proliferation/cytotoxicity assay, covering > 20 cancer types, e.g. Liver, Lung, Breast, Lymphoma, Colon, Melanoma, Leukemia and Myeloma tumors. After the in vitro screen, the most sensitive cancer cell lines can be selected for further testing in xenograft or orthotopic tumor models in mice or rats.
More Info
PharmaLegacy provides a panel of extensively-validated syngeneic mouse models for preclinical immunotherapy research, used to interrogate novel immuno-oncology treatments. We have multiple syngeneic model types including subcutaneous, orthotopic and metastatic models. Our suite of syngeneic mouse models includes over 30 models covering over 20 cancer types, and have been validated with anti-PD-1, anti-PD-L1, anti-CTLA-4 etc. antibodies. Additional models are in development.
World-Class Capabilities for Demanding Oncology Studies
PharmaLegacy’s AAALAC-accredited laboratories are equipped to house more than 30,000 animals. We have numerous proprietary platforms and models which allow us to provide uniquely rich data. All our work is FDA CFR 21 Part 11 compliant. We provide expedited reports for regulatory filings. Clients even have the option of remotely monitoring their studies by live video. Everything we do is with quality, customer service, and IP protection in mind.
Our substantial vivarium capacity also allows us to maintain a huge number of models in stock, ready to immediately deploy in your studies. Contact us today and we can be generating data for you in under two weeks.
The Best Preclinical Oncology CRO
You may be familiar with the “Iron Triangle” principle, which states that you can only get two out of the three between price, cost, and quality. The only thing which can break the rule is technological or operational improvements which did not previously exist in the market.
Well, we operate differently.
PharmaLegacy is built to provide better, faster, and less expensive preclinical oncology studies. From our giant catalog of readily available models, our scientific staff averaging over 15 years of experience, and our surprisingly affordable pricing, when you choose PharmaLegacy as your preclinical oncology CRO, you can expect more.
More than 100 types of cancer exist, each one having multiple subtypes. This has led to the development of a plethora of models that accurately replicate both the host and the tumor microenvironment, allowing new treatments to be tailored in accordance with optimal biological dynamics.
The only thing you need to advance your next cancer research breakthrough is the right partner – a partner you’ll find in PharmaLegacy. Contact us today and let’s move your pipeline forward.
“The study they delivered on a very reasonable budget was top notch […] The model was executed flawlessly.”
See why a top-20 pharmaceutical company trusts PharmaLegacy for its preclinical immuno-oncology trials.
